XML 62 R51.htm IDEA: XBRL DOCUMENT v3.5.0.2
Research and Collaboration Agreements - AbbVie Ireland Unlimited Company - Additional Information (Details) - AbbVie Ireland Unlimited Company
1 Months Ended 3 Months Ended 9 Months Ended
Apr. 30, 2016
USD ($)
Target
Agreement
AccountingUnit
Sep. 30, 2016
USD ($)
Sep. 30, 2016
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Number of accounting units | AccountingUnit 2    
Estimated research service period     5 years
Revenue recognized from collaborative arrangement   $ 1,000,000 $ 1,800,000
Collaborative Arrangement      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Number of collaboration agreements | Agreement 2    
Percentage of net profits or net losses related to development costs 35.00%    
Collaborative Arrangement | Up Front Payment Arrangement      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Upfront payment received $ 10,000,000    
Collaborative Arrangement | Maximum      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Number of undetermined targets | Target 2    
Collaborative Arrangement | Maximum | Development, Regulatory and Commercial Milestone Payments      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Contingent milestone payments receivable $ 275,000,000    
CD71 Agreement      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Deferred revenue   18,800,000 18,800,000
CD71 Agreement | Up Front Payment Arrangement      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Upfront payment received 20,000,000    
CD71 Agreement | Maximum      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Contingent payments receivable upon achieving development, regulatory and commercial milestones $ 470,000,000    
Discovery Agreement      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Deferred revenue   $ 9,400,000 $ 9,400,000